15
views
0
recommends
+1 Recommend
3 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Clinical Features of Patients with Coronavirus Disease 2019 (COVID‐19) from a Designated Hospital in Beijing, China

      research-article

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Clinical and laboratory data available on patients with coronavirus disease 2019 (COVID‐19) in Beijing, China remain extremely limited. Here, we summarized the clinical characteristics of patients with COVID‐19 in a designated hospital in Beijing, China.

          55 patients with laboratory‐confirmed SARS‐CoV‐2 infection were admitted to Beijing 302 Hospital and enrolled in this study. Demographic data, symptoms, comorbidities, laboratory values, treatments, and clinical outcomes were all collected and retrospectively analyzed.

          15 (27.3%) of the patients had non‐severe symptom, the mean age was 44.0 years (interquartile range 34.0‐56.0), and median incubation period was 7.5 days (interquartile range 5.0‐11.8). 26 (47.3%) patients had exposure history in Wuhan while 20 (36.4%) were associated with familial clusters. 18 (32.7%) had underlying comorbidities including hypertension. The most common symptoms of illness were fever (45, 81.8%), 51 (92.7%) patients had abnormal findings on chest CT. Laboratory findings showed that neutrophil count, percentage of lymphocyte, percentage of eosinophil, eosinophil count, erythrocyte sedimentation rate, albumin, and serum ferritin are potential risk factors for patients with poor prognosis. 26 patients (47.3%) were still hospitalized while 29 (52.7%) had been discharged at this point.

          Compared with patients in Wuhan, the symptoms of patients in Beijing are relatively mild. Older age, more comorbidities, and more abnormal prominent laboratory markers were associated with severe condition. On the basis of antiviral drugs, antibiotics treatment, appropriate dosage of corticosteroid and gamma globulin therapy significantly improve patients’ outcomes. Early identification and timely medical treatment are important to reduce the severity of patients with COVID‐19.

          This article is protected by copyright. All rights reserved.

          Related collections

          Author and article information

          Contributors
          fanhuahao@mail.buct.edu.cn
          Journal
          J Med Virol
          J. Med. Virol
          10.1002/(ISSN)1096-9071
          JMV
          Journal of Medical Virology
          John Wiley and Sons Inc. (Hoboken )
          0146-6615
          1096-9071
          05 May 2020
          : 10.1002/jmv.25966
          Affiliations
          [ 1 ] Research Center for Clinical and Translational Medicine, Beijing 302 Hospital/The Fifth Medical Center of PLA General Hospital Beijing China
          [ 2 ] The First Liver Cirrhosis Diagnosis and Treatment Center, Beijing 302 Hospital/the Fifth Medical Center of Chinese PLA General Hospital Beijing China
          [ 3 ] Institute of Cerebrovascular Disease Research and Department of Neurology Xuanwu Hospital of Capital Medical University Beijing China
          [ 4 ] Medical Information Center Department Beijing 302 Hospital/the Fifth Medical Center of Chinese PLA General Hospital Beijing China
          [ 5 ] Library, Beijing 302 Hospital/the Fifth Medical Center of Chinese PLA General Hospital Beijing China
          [ 6 ] The Medical Center of Clinical Laboratory, Beijing 302 Hospital/the Fifth Medical Center of Chinese PLA General Hospital Beijing China
          [ 7 ] Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology Beijing China
          Author notes
          [*] [* ] Correspondence Huahao Fan, Beijing Advanced Innovation Center for Soft Matter Science and Engineering, College of Life Science and Technology, Beijing University of Chemical Technology, Beijing, China.

          Email: fanhuahao@ 123456mail.buct.edu.cn

          Jingfeng Bi, Research Center for Clinical and Translational Medicine, Beijing 302 Hospital/The Fifth Medical Center of PLA General Hospital, Beijing, China.

          Email: 123bjf@ 123456163.com

          [†]

          These authors contributed equally to this article.

          [‡]

          These authors contributed equally to this article.

          Author information
          http://orcid.org/0000-0001-5007-2158
          Article
          JMV25966
          10.1002/jmv.25966
          7267635
          32369208
          f4d4f159-f029-4823-ba6f-144c8204fa00
          This article is protected by copyright. All rights reserved.

          This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.

          History
          Page count
          Figures: 0, Tables: 0, Pages: 44, Words: 585
          Categories
          Research Article
          Research Articles
          Custom metadata
          2.0
          accepted-manuscript
          Converter:WILEY_ML3GV2_TO_JATSPMC version:5.8.3 mode:remove_FC converted:03.06.2020

          Microbiology & Virology
          clinical features,coronavirus disease 2019,designated hospital in beijing,sars‐cov‐2

          Comments

          Comment on this article